Journal of Neural Transmission

Article	Citations
Do demographic and clinical features and comorbidities affect the risk of spread to an additional body site in functional motor disorders?	88
Alterations in metabolites in the anterior cingulate cortex and thalamus and their associations with pain and empathy in patients with chronic mild pain: a preliminary study	87
Proteinopathies: molecular mechanisms and diagnostic perspectives	62
Facets of movement disorders– a tribute to Heinz Reichmann	62
Eye movement study in essential tremor patients and its clinical correlates	56
Current perspectives on brain circuits involved in food addiction-like behaviors	55
A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response:	54
A wearable device-enabled therapeutic approach to improve joint attention in autism spectrum disorder: a prospective pilot study	53
Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes	52
Pathogenesis of Parkinson’s disease: from hints from monogenic familial PD to biomarkers	51
Distinct gait dimensions are modulated by physical activity in Parkinson's disease patients	44
Celebrating the career of professor Zdravko Lacković: a life in neuroscience, pharmacology, and discovery	44
Sitagliptin attenuates L-dopa-induced dyskinesia by regulating mitochondrial proteins and neuronal activity in a 6-OHDA-induced mouse model of Parkinson’s disease	40
Movement disorders associated with diarrhoea	40
Contrasting features between Tourette syndrome and secondary tic disorders	39
Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson’s disease	37
Stress enhances heartbeat-evoked potentials, independent of continuous or intermittent theta burst stimulation of the interoceptive brain network targeting the right supramarginal gyrus: a preliminary	37
Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up	37
Dopamine agonists in the treatment of Parkinson's disease: the show must go on	36
Non motor Parkinson: subtypes, biomarkers, stepped care and a journal!	35
Bradykinesia and rigidity modulated by functional connectivity between the primary motor cortex and globus pallidus in Parkinson’s disease	35
Camillo Golgi’s contributions to the anatomic basis of sensitivity in tendons	32
Association between autonomic dysfunction with motor and non-motor symptoms in patients with Parkinson's disease	30
Botulinum toxin and conservative treatment strategies in people with cervical dystonia: an online survey	30
Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer’s disease therapy	29

Unusual delayed and prolonged arm weakness and atrophy following botulinum toxin injection for musician’s cramp: case report	29
The pathobiology of depression in Huntington’s disease: an unresolved puzzle	28
Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research	28
Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study	27
Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016	26
The spectrum of behavioral disorders in amyotrophic lateral sclerosis: current view	26
The role of immune and inflammatory-related indicators in cognitive dysfunction and disease severity in patients with parkinson’s disease	25
Unravelling head tremor mechanisms: insights from speech analysis in essential tremor and cervical dystonia	25
Reduced vagal activity in borderline personality disorder is unaffected by intranasal oxytocin administration, but predicted by the interaction between childhood trauma and attachment insecurity	23
Constipation and pain in Parkinson’s disease: a clinical analysis	23
Impact of APOE and MAPT genetic profile on the cognitive functions among Amyotrophic Lateral Sclerosis Tunisian patients	22
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease	22
Illness perceptions in pre-operative Parkinson’s disease patients	22
MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy	21
Regulation of circadian gene activity in fibroblasts from ADHD patients through Rosiglitazone: a pilot study	21
The relationship of early life adversity and physiological synchrony within the therapeutic triad in horse-assisted therapy	21
Insulin resistance: fueling oxidative stress and neurodegeneration	20
Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice	19
The corticospinal tract in multiple sclerosis: correlation between cortical excitability and magnetic resonance imaging measures	19
A call to action: revitalizing the German parkinson’s research ecosystem post-pandemic	19
Prenatal exposure to morphine enhances excitability in locus coeruleus neurons	17
Drug repurposing and new drug targets: perspectives for novel treatment options in mental health disorders	17
Axial postural abnormalities and pain in Parkinson’s disease	17
The brainstem reticular formation pivots abnormal neural transmission in the course of Anorexia Nervosa	17
Old problems, new solutions: harnessing technology and innovation in Parkinson’s disease—evidence and experiences from Thailand	17
Sleep disorders among frontline nurses after the COVID-19 outbreak: a large-scale cross-sectional study	17
Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration	16
Proteinopathies associated to repeat expansion disorders	16
Serum glial fibrillary acidic protein is elevated in early-stage late-onset essential tremor and associated with tremor progression	16
Advanced therapy in advanced Parkinson’s disease: money’s too tight to mention	16
Small intestinal bacterial overgrowth in Alzheimer’s disease	16
Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice	16
In situ stoichiometry amounts of p62 and poly-ubiquitin exceed the increase of alpha-synuclein during degeneration of catecholamine cells induced by autophagy inhibition in vitro	15
Autism Spectrum Disorder and auditory sensory alterations: a systematic review on the integrity of cognitive and neuronal functions related to auditory processing	15
Psychological, neuroendocrine and inflammatory stress responses in women after miscarriage or stillbirth: investigating early psychobiological adaptations to potential traumatic events	15
Potentially inappropriate medications according to PRISCUS list and FORTA (Fit fOR The Aged) classification in geriatric psychiatry: a cross-sectional study	14
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone	14
The two-network framework of number processing: a step towards a better understanding of the neural origins of developmental dyscalculia	14
Neuroscience and addiction research: current advances and perspectives	14
Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease	14
Language in autism: domains, profiles and co-occurring conditions	14
Atrophy of cerebellar lobule VI and primary motor cortex in cervical dystonia - a region of interest-based study	14
Update on sleep disorders in advanced Parkinson’s disease: a narrative review	14
MAOA methylation is associated with impulsive and antisocial behaviour: dependence on allelic variation, family environment and diet	14
From the tyrosine hydroxylase hypothesis of Parkinson’s disease to modern strategies: a short historical overview	13
The natural course of idiopathic cervical dystonia	13
Superoxide dismutase isozymes in cerebral organoids from autism spectrum disorder patients	13
Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study	13
The impact of cerebral vasomotor reactivity on cerebrovascular diseases and cognitive impairment	13
Exploring developmental trajectories throughout adolescence of children with autism spectrum disorder without intellectual disability	13

A historical review of multiple system atrophy with a critical appraisal of cellular and animal models	13
Increased hair cortisol in mothers of children with ADHD symptoms and psychosocial adversity background	12
Issues for patchy tissues: defining roles for gut-associated lymphoid tissue in neurodevelopment and disease	12
Exploring transferability in psychiatric interventions: a conceptual framework	12
Sex differences in schizophrenia: a longitudinal methylome analysis	12
The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease	12
Sexual dysfunction in men with young onset Parkinson's disease	12
Tips and tricks in tremor treatment	12
Clinimetrics of the Italian version of the Montreal Cognitive Assessment (MoCA) in adult-onset idiopathic focal dystonia	11
Unveiling the link between chronic pain and misuse of opioids and cannabis	11
Oligodendrocytes matter: a review of animal studies on early adversity	11
Writing tremor in Parkinson’s disease: frequency and associated clinical features	11
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease	11
Perceived social support declines after deep brain stimulation surgery in patients with Parkinson’s disease	11
Patterns of striatal dopamine depletion and motor deficits in de novo Parkinson’s disease	11
Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS	11
Therapeutic use of medical Cannabis in neurological diseases: a clinical update	11
Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA	11
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide	11
Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels	10
Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes	10
Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes	10
A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A	10
Mild cognitive impairment in amyotrophic lateral sclerosis: current view	10
Maternal separation and its developmental consequences on anxiety and parvalbumin interneurons in the amygdala	10
Usability of the digit-tracking technique in a geriatric population of inpatients with and without neurocognitive disorders: The DIGICOG-start study	10
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations	10
Plasma prolactin and symptoms of schizophrenia	10
If you can't be with the one you love, love the one you're with (C, S, N & Y)	10
Protein clearance strategies for disease intervention	10
High-dose glucocorticoids in COVID-19 patients with acute encephalopathy: clinical and imaging findings in a retrospective cohort study	10
Neuromarkers in addiction: definitions, development strategies, and recent advances	10
RNA sequencing of the thalamus and rostral ventral medulla in rats with chronic orofacial pain	10
Depression and anxiety in multiple sclerosis. Review of a fatal combination	9
MEF2C gene variations are associated with ADHD in the Chinese Han population: a case–control study	9
The akinetic crisis in Parkinson´s disease- the upper end of a spectrum of subacute akinetic states	9
Polymorphisms of COMT and CREB1 are associated with treatment-resistant depression in a Chinese Han population	9
A smartphone-based tapping task as a marker of medication response in Parkinson’s disease: a proof of concept study	9
Differential diagnosis of Huntington’s disease− neurological aspects of NKX2-1-related disorders	9
Treatment; Moussa B.H. Youdim	9
Correlation between the MNCD classification-based staging of Parkinson’s disease and quality of life: a cross-sectional study	9
Advanced is advanced is advanced is advanced	9
Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer’s disease	9
Depression in dementia with Lewy bodies: a critical update	9
Correction: The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies	9
Environmental opportunities facilitating cognitive development in preschoolers: development of a multicriteria index	9
The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study	9
Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s disease	9
The heterogeneity of Parkinson’s disease	8
Catecholamines and Parkinson’s disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview	8
Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson’s disease	8
Iron and copper ions accelerate and modify dopamine oxidation to eumelanin: implications for neuromelanin genesis	8
The sex-specific relationship of ghrelin and cognition in Chinese han first-episode drug-naive major depressive disorder	8
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone	8
From parents to children: associations of traffic risks with impulsivity, family relationships and serotonin transporter genotype	8
The pathobiological basis of depression in Parkinson disease: challenges and outlooks	8
Mild cognitive impairment in Huntington’s disease: challenges and outlooks	8
Association of polygenic risk scores, traumatic life events and coping strategies with war-related PTSD diagnosis and symptom severity in the South Eastern Europe (SEE)-PTSD cohort	8
Facial emotion recognition deficits are associated with hypomimia and related brain correlates in Parkinson’s disease	8
The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates	8
Cognition and Activity of Daily Living Function in people with Parkinson’s disease	8
SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t	8
The effect of recombinant botulinum neurotoxin A on neuropathic pain in the spared nerve injury mouse model	8
Psychotherapies in opioid use disorder: toward a step-care model	8
Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?	8
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome	8
Mild cognitive impairment in multiple system atrophy: a brain network disorder	8
Driving innovation in addiction treatment: role of transcranial magnetic stimulation	8
Neurogenic orthostatic hypotension in Parkinson’s disease: is there a role for locus coeruleus magnetic resonance imaging?	8
Locus Coeruleus magnetic resonance imaging: a comparison between native-space and template-space approach	8
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice	8
Concomitant pathologies and their impact on Huntington’s disease. A brief review of current evidence	7
A structured framework for emotion-cognition dynamics: Implications for assessment and intervention	7
Genetic and environmental mouse models of autism reproduce the spectrum of the disease	7
Botulinum toxin therapy: past, present and future developments	7
Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network	7
Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review	7
GBA-associated PD: chances and obstacles for targeted treatment strategies	7
Drug interactions in a sample of inpatients diagnosed with cannabis use disorder	7
Interrater reliability of motor severity scales for hemifacial spasm	7

Association between alcohol consumption and mortality in Parkinson’s disease	7
Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease	7
Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review	7
Probing the properties of PTEN specific botulinum toxin type E mutants	7
Clinical correlates of pareidolias and color discrimination deficits in idiopathic REM sleep behavior disorder and Parkinson’s disease	7
Bioinformatics approach reveals the critical role of the NOD-like receptor signaling pathway in COVID-19-associated multiple sclerosis syndrome	7
The impact of short-term blood pressure variability on cognitive decline in Parkinson’s disease patients without co-morbidities	7
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?	7
Plasma concentrations of anti-inflammatory cytokine TGF-β are associated with hippocampal structure related to explicit memory performance in older adults	7
Nicotinic regulation of microglia: potential contributions to addiction	7
Correction to: Neuropathology of multiple system atrophy: Kurt Jellinger`s legacy	7
Time-course of decline in different cognitive domains in Parkinson’s disease: a retrospective study	7
Reduced interleukin-6 stress reactivity in male physicians with occupational burnout	6
Correction: Revolutionizing our understanding of Parkinson’s disease: Dr. Heinz Reichmann’s pioneering research and future research direction	6
Recent developments in stress and anxiety research	6
Disease modification in Parkinsonism: obstacles and ways forward	6
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?	6
Motor and non-motor fluctuations in Parkinson’s disease: the knowns and unknowns of current therapeutic approaches	6
Neurodevelopmental disorders (NDD) without boundaries: research and interventions beyond classifications	6
Steroid hormone pathways, vitamin D and autism: a systematic review	6
Identification of DAGLB variants in Japanese early-onset Parkinson’s disease	6
Essential tremor plus rest tremor: current concepts and controversies	6
Insulin signaling disruption exacerbates memory impairment and seizure susceptibility in an epilepsy model with Alzheimer’s disease-like pathology	6
Predisposing factors to pattern change in cervical dystonia	6
Sex- and age-specific prevalence and risk factors of depressive symptoms in Parkinson’s disease	6
Parkinson's Disease Multidisciplinary Complex Therapy (PD-MCT): appreciation of its current function for the treatment of people with Parkinson’s disease in Germany and the needs of future development	6
Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis	6
Insights into insulin signalling and oxidative stress in the Tg2576 mouse model of familial Alzheimer’s disease: effects of chronic oral galactose administration	6
MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia	6
Clinical and kinematic characterization of parkinsonian soft signs in essential tremor	6
Deep brain stimulation in progressive supranuclear palsy: a dead-end story? A narrative review	6
Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016	6
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease	6
Correction to: Common network effect‑patterns after monoamine reuptake inhibition in dissociated hippocampus cultures	6
Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study	6
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease	6
Vascular parkinsonism: an update	6
Diagnostic and therapeutic challenges in PD-associated non-motor symptoms: the roles of neurologists and consultant physicians	6
A cross-language speech model for detection of Parkinson’s disease	6
Brain instability in dynamic functional connectivity in schizophrenia	5
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry	5
The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder	5
ADHD and associated psychopathology in older adults in a German community sample	5
Behavioral disorders in Parkinson disease: current view	5
COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study	5
Neurobiological mechanisms of dialectical behavior therapy and Morita therapy, two psychotherapies inspired by Zen	5
Premorbid de novo artistic creativity in frontotemporal dementia (FTD) syndromes	5
The relationship between sphingomyelin and ceramide levels and soft neurological signs in ADHD	5
The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies	5
Current trends in basic research on Parkinson’s disease: from mitochondria, lysosome to α-synuclein	5
Excessive psychological stress preceding the onset of idiopathic cervical dystonia	5
Special issue in honor of Peter Riederer at the occasion of his 80th birthday	5
Mitochondrial dysfunction in Parkinson’s disease	5
Multilevel and multimodal biobehavioral methods in the study of stress, trauma, and resilience: a systems approach	5
Viruses, parkinsonism and Parkinson’s disease: the past, present and future	5
Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress	5
Is the vertex a good control stimulation site? Theta burst stimulation in healthy controls	5
The specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP-intoxicated mice	5
Neural bases characterizing chronic and severe upper-limb motor deficits after brain lesion	5
Cannabis use, abuse and dependence during the COVID-19 pandemic: a scoping review	5
Editorial for Emeritus Professor Yoshikuni Mizuno	5
Prof. DDr. Gregor K. Wenning (1964–2024)	5
Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study	5
Oculometric measures as a tool for assessment of clinical symptoms and severity of Parkinson’s disease	5
Between-sex variability of resting state functional brain networks in amyotrophic lateral sclerosis (ALS)	4
Spasmodic dysphonia: the need for a combined neurological and phoniatric approach	4
Temporal onset of non-motor symptoms and the body-first/brain-first dichotomy in Parkinson’s disease: a cross-sectional single center experience	4
Correction to: Proteinopathies: molecular mechanisms and diagnostic perspectives	4
Declining incidence of Parkinson’s disease in Israel (2002–2021)	4
The ‘α-synucleinopathy syndicate’: multiple system atrophy and Parkinson’s disease	4
Action impulsivity and attention deficits in patients at an early stage of Huntington disease	4
Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy (MT); comparison of three established psychotherapies and possible common neural mechanisms of psychothe	4
More than fear? Brain activation patterns of dental phobic patients before and after an exposure-based treatment	4
Renaming of Hallervorden–Spatz disease: the second man behind the name of the disease	4
Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies	4
Prevalence and impact of comorbidities in amyotrophic lateral sclerosis	4
Neuroplasticity in Parkinson’s disease	4
Neuroscience in addiction research	4
Altered domain-specific striatal functional connectivity in patients with Parkinson’s disease and urinary symptoms	4
Approaching therapy of Alzheimer’s disease via the antidiabetic drug liraglutide—a study with streptozotocin intracerebroventricularly treated Wistar rats	4
Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pha	4
Dopamine denervation in the functional territories of the striatum: a new MR and atlas-based 123I-FP-CIT SPECT quantification method	4
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study	4
Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes	4
Treadmill training and physiotherapy similarly improve dual task gait performance: a randomized-controlled trial in Parkinson’s disease	4
Glutathione S-transferase polymorphisms (GSTM1/GSTT1) outcomes in clinical profile and treatment responsiveness among Tunisian cohort of Parkinson’s disease	4
Possible improvement of social adjustment after subthalamic deep brain stimulation in people with Parkinson’s disease? A systematic review and meta-analysis	4
Deep brain stimulation for psychostimulant use disorders	4
Modulatory effect of olanzapine on neuronal nitric oxide synthase (nNOS) expression in the rat striatum	4
Genetic testing for Parkinson’s disease in clinical practice	4
The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models	4
The effectiveness of non-invasive brain stimulation in treatment of major depressive disorder (MDD): a systematic review and transfer analysis	4
Eyes as a window to brain pathology in parkinson’s disease: a narrative review	3
Headache patterns in patent foramen ovale patients: beyond migraine with aura	3
Does botulinum toxin affect psycho-social aspects in dystonia?	3